Marit Ahrens

Arnold Heller Str. 3
Kiel, SH 24105, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

Journal: Cancer treatment and research communications

Published: May 03, 2026

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 21, 2026

Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group.

Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group.

Journal: International journal of cancer

Published: July 03, 2025

Influence of PSA level at salvage radiotherapy on metastasis-free survival following radical prostatectomy.

Influence of PSA level at salvage radiotherapy on metastasis-free survival following radical prostatectomy.

Journal: World journal of urology

Published: May 21, 2025

Radical Prostatectomy Versus Radiation Therapy for Locally Advanced and Clinically Nodal Positive Prostate Cancer.

Radical Prostatectomy Versus Radiation Therapy for Locally Advanced and Clinically Nodal Positive Prostate Cancer.

Journal: Clinical genitourinary cancer

Published: March 14, 2025

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 17, 2025

Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomy.

Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomy.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: November 05, 2024

Radical Prostatectomy Versus Radiotherapy for Prostate Cancer: Stage-, Age-, and Frailty-Specific Cancer-Control Outcomes of 2600 Patients.

Radical Prostatectomy Versus Radiotherapy for Prostate Cancer: Stage-, Age-, and Frailty-Specific Cancer-Control Outcomes of 2600 Patients.

Journal: Deutsches Arzteblatt international

Published: October 19, 2024

Non-clear cell renal cell carcinoma

Non-clear cell renal cell carcinoma

Journal: Urologie (Heidelberg, Germany)

Published: October 11, 2024

Association between frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancer.

Association between frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancer.

Journal: Urologic oncology

Published: September 29, 2024

Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer.

Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer.

Journal: The Prostate

Published: May 08, 2024

Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities.

Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 08, 2022

Showing 1-12 of 27

Last Updated: 09/26/2026